AR128678A1 - Nickasas cas12a - Google Patents
Nickasas cas12aInfo
- Publication number
- AR128678A1 AR128678A1 ARP230100518A ARP230100518A AR128678A1 AR 128678 A1 AR128678 A1 AR 128678A1 AR P230100518 A ARP230100518 A AR P230100518A AR P230100518 A ARP230100518 A AR P230100518A AR 128678 A1 AR128678 A1 AR 128678A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- acid molecule
- activity
- encodes
- engineered
- Prior art date
Links
- 108700004991 Cas12a Proteins 0.000 title abstract 9
- 101150059443 cas12a gene Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 8
- 108020004707 nucleic acids Proteins 0.000 abstract 8
- 102000039446 nucleic acids Human genes 0.000 abstract 8
- 150000007523 nucleic acids Chemical class 0.000 abstract 8
- 108010008532 Deoxyribonuclease I Proteins 0.000 abstract 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 abstract 6
- 108020005004 Guide RNA Proteins 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108020004705 Codon Proteins 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 210000001808 exosome Anatomy 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 238000010362 genome editing Methods 0.000 abstract 1
- -1 lipid nanoparticles Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
En el campo de la edición del genoma génico, una enzima Cas12a que tiene actividad de nickasa, así como también los medios y métodos para la modificación de un locus genómico de interés con una enzima Cas12a que tiene actividad de nickasa y usos de estos. Reivindicación 8: Una molécula de ácido nucleico que codifica la enzima Cas12a o el fragmento catalíticamente activo de esta de acuerdo con cualquiera de las reivindicaciones anteriores, opcionalmente, caracterizada porque la molécula de ácido nucleico está optimizada por codones, preferentemente optimizada por codones para una célula fúngica, incluso una célula de levadura, una célula procariota o una célula de arquea, y/o comprende una molécula de ácido nucleico que codifica al menos un ARN guía. Reivindicación 10: Un constructo o vector de expresión caracterizado porque comprende al menos una molécula de ácido nucleico de acuerdo con la reivindicación 8 o 9. Reivindicación 11: Una célula caracterizada porque comprende al menos una enzima Cas12a diseñada por ingeniería genética o un fragmento catalíticamente activo de esta de acuerdo con cualquiera de las reivindicaciones 1 a 7; y/o al menos una molécula de ácido nucleico de acuerdo con la reivindicación 8 o 9; y/o al menos un constructo o vector de expresión de acuerdo con la reivindicación 10. Reivindicación 16: Una proteína de fusión o al menos una molécula de ácido nucleico que la codifica, caracterizada porque comprende al menos una enzima Cas12a diseñada por ingeniería genética que tiene actividad de nickasa o el fragmento catalíticamente activo de esta de acuerdo con cualquiera de las reivindicaciones 1 a 7, unida covalente y/o no covalentemente a al menos un dominio de polipéptido adicional, en donde el al menos un dominio de polipéptido adicional tiene una actividad seleccionada de una actividad enzimática, actividad de unión o actividad de direccionamiento, y que comprende opcionalmente al menos un ARN guía compatible con la enzima Cas12a diseñada por ingeniería genética que tiene actividad de nickasa, en donde el al menos un ARN guía compatible interactúa covalente y/o no covalentemente con la al menos una enzima Cas12a diseñada por ingeniería genética que tiene actividad de nickasa o el fragmento catalíticamente activo de esta. Reivindicación 19: Un kit caracterizado porque comprende (i) una enzima Cas12a diseñada por ingeniería genética que tiene actividad de nickasa (nCas12a), o un fragmento catalíticamente activo de esta como se define en cualquiera de las reivindicaciones 1 a 7, o un constructo o vector de expresión como se define en la reivindicación 10, o un complejo como se define en la reivindicación 15, o al menos una secuencia que lo codifica, o una proteína de fusión como se define en la reivindicación 16, o al menos una secuencia que la codifica, o un editor base de adenina o citidina, o un complejo editor de base, o al menos una molécula de ácido nucleico que lo codifica como se define en la reivindicación 17, o un editor de calidad o un complejo editor de calidad, o al menos una molécula de ácido nucleico que lo codifica como se define en la reivindicación 18; (ii) al menos un ARN guía compatible, o un conjunto de ARN guía compatibles, en donde cada ARN guía es complementario a las secuencias diana de interés; y (iii) un conjunto de reactivos; (iv) que comprende opcionalmente partículas, vesículas, o al menos un vector, incluso un vector viral, para asistir en la administración, en donde dichas partículas comprenden un lípido, incluso nanopartículas lipídicas, un azúcar, un metal o un polipéptido, o una combinación de estos, o en donde dichas vesículas comprenden exosomas o liposomas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159465 | 2022-03-01 | ||
| EP22202125 | 2022-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128678A1 true AR128678A1 (es) | 2024-06-05 |
Family
ID=85384366
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100519A AR128679A1 (es) | 2022-03-01 | 2023-03-01 | Nickasas cas12a |
| ARP230100518A AR128678A1 (es) | 2022-03-01 | 2023-03-01 | Nickasas cas12a |
| ARP230100520A AR128680A1 (es) | 2022-03-01 | 2023-03-01 | Nickasas cas12a |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100519A AR128679A1 (es) | 2022-03-01 | 2023-03-01 | Nickasas cas12a |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100520A AR128680A1 (es) | 2022-03-01 | 2023-03-01 | Nickasas cas12a |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230374480A1 (es) |
| AR (3) | AR128679A1 (es) |
| AU (2) | AU2023227365A1 (es) |
| IL (2) | IL315225A (es) |
| TW (3) | TW202342756A (es) |
| WO (3) | WO2023166030A1 (es) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2018274T5 (es) | 1986-03-11 | 1996-12-16 | Plant Genetic Systems Nv | Celulas vegetales resistentes a los inhibidores de glutamina sintetasa, preparadas por ingenieria genetica. |
| AU639319B2 (en) | 1990-04-04 | 1993-07-22 | Pioneer Hi-Bred International, Inc. | Production of improved rapeseed exhibiting a reduced saturated fatty acid content |
| FR2673643B1 (fr) | 1991-03-05 | 1993-05-21 | Rhone Poulenc Agrochimie | Peptide de transit pour l'insertion d'un gene etranger dans un gene vegetal et plantes transformees en utilisant ce peptide. |
| FR2673642B1 (fr) | 1991-03-05 | 1994-08-12 | Rhone Poulenc Agrochimie | Gene chimere comprenant un promoteur capable de conferer a une plante une tolerance accrue au glyphosate. |
| US6509516B1 (en) | 1999-10-29 | 2003-01-21 | Plant Genetic Systems N.V. | Male-sterile brassica plants and methods for producing same |
| US6506963B1 (en) | 1999-12-08 | 2003-01-14 | Plant Genetic Systems, N.V. | Hybrid winter oilseed rape and methods for producing same |
| CN101688220B (zh) | 2007-07-09 | 2017-04-05 | 拜尔作物科学公司 | 包含突变酰基‑acp硫酯酶等位基因的芸苔属植物 |
| CN103898042B (zh) | 2007-11-28 | 2018-05-01 | 拜尔作物科学公司 | 包含突变indehiscent等位基因的芸苔属植物 |
| EP2304038B1 (en) | 2008-07-17 | 2016-08-31 | Bayer CropScience NV | Brassica plant comprising a mutant indehiscent allelle |
| SI2501804T1 (sl) | 2009-11-20 | 2016-09-30 | Bayer Cropscience Nv | Rastline Brassice, ki vsebujejo mutirane FAD3 alele |
| EP3868880A1 (en) | 2016-04-29 | 2021-08-25 | Basf Plant Science Company GmbH | Improved methods for modification of target nucleic acids |
| US11168313B2 (en) | 2016-07-26 | 2021-11-09 | The General Hospital Corporation | Variants of CRISPR from Prevotella and Francisella 1 (Cpf1) |
| WO2018195545A2 (en) | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| WO2018213726A1 (en) * | 2017-05-18 | 2018-11-22 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| US20210079366A1 (en) * | 2017-12-22 | 2021-03-18 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| MX2020013229A (es) | 2018-06-04 | 2021-04-28 | Univ Copenhagen | Endonucleasas cpf1 mutantes. |
| KR20210042130A (ko) | 2018-08-08 | 2021-04-16 | 인티그레이티드 디엔에이 테크놀로지스 아이엔씨. | Acidaminococcus sp. cpf1의 dna 절단 활성을 향상시키는 신규한 돌연변이 |
| WO2020191243A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| CA3158555A1 (en) * | 2019-10-23 | 2021-04-29 | Pairwise Plants Services, Inc. | Compositions and methods for rna-templated editing in plants |
| AU2020410138A1 (en) | 2019-12-16 | 2022-06-23 | BASF Agricultural Solutions Seed US LLC | Precise introduction of DNA or mutations into the genome of wheat |
| US20230042273A1 (en) | 2019-12-16 | 2023-02-09 | BASF Agricultural Solutions Seed US LLC | Improved genome editing using paired nickases |
| WO2021175759A1 (en) | 2020-03-04 | 2021-09-10 | Basf Se | Method for the production of constitutive bacterial promoters conferring low to medium expression |
| JP2023524066A (ja) * | 2020-05-01 | 2023-06-08 | インテグレーティッド ディーエヌエイ テクノロジーズ インコーポレーティッド | 非カノニカルｔｔｔｔプロトスペーサー隣接モチーフにて増強された切断活性を備えるラクノスピラセｓｐ．のｃａｓ１２ａ変異体 |
-
2023
- 2023-03-01 TW TW112107419A patent/TW202342756A/zh unknown
- 2023-03-01 AR ARP230100519A patent/AR128679A1/es unknown
- 2023-03-01 IL IL315225A patent/IL315225A/en unknown
- 2023-03-01 AU AU2023227365A patent/AU2023227365A1/en active Pending
- 2023-03-01 IL IL315220A patent/IL315220A/en unknown
- 2023-03-01 AU AU2023228036A patent/AU2023228036A1/en active Pending
- 2023-03-01 WO PCT/EP2023/055134 patent/WO2023166030A1/en active Application Filing
- 2023-03-01 WO PCT/EP2023/055137 patent/WO2023166032A1/en active Application Filing
- 2023-03-01 TW TW112107412A patent/TW202342754A/zh unknown
- 2023-03-01 WO PCT/EP2023/055130 patent/WO2023166029A1/en active Application Filing
- 2023-03-01 US US18/176,874 patent/US20230374480A1/en active Pending
- 2023-03-01 TW TW112107418A patent/TW202342744A/zh unknown
- 2023-03-01 AR ARP230100518A patent/AR128678A1/es unknown
- 2023-03-01 AR ARP230100520A patent/AR128680A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023166032A1 (en) | 2023-09-07 |
| WO2023166029A1 (en) | 2023-09-07 |
| AU2023228036A1 (en) | 2024-09-12 |
| TW202342756A (zh) | 2023-11-01 |
| AR128680A1 (es) | 2024-06-05 |
| TW202342744A (zh) | 2023-11-01 |
| AU2023227365A1 (en) | 2024-09-12 |
| US20230374480A1 (en) | 2023-11-23 |
| IL315225A (en) | 2024-10-01 |
| TW202342754A (zh) | 2023-11-01 |
| WO2023166030A1 (en) | 2023-09-07 |
| AR128679A1 (es) | 2024-06-05 |
| IL315220A (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220098587A1 (en) | Methods and compositions for editing rnas | |
| EP3864152B1 (en) | Methods and compositions for editing rnas | |
| AU2016206870B2 (en) | Gene editing through microfluidic delivery | |
| US20230021641A1 (en) | Cas9 variants having non-canonical pam specificities and uses thereof | |
| CA3036926C (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| JP7449646B2 (ja) | 細胞および組織への遺伝子編集タンパク質および組成物の、ベクターなしでの送達 | |
| JP2023168355A (ja) | 改良された相同組換えおよびその組成物のための方法 | |
| TW202028461A (zh) | 核酸構築體及使用方法 | |
| JP6284181B2 (ja) | 環状ｒｎａ及びタンパク質の製造方法 | |
| GB2617658A (en) | Class II, type V CRISPR systems | |
| RU2707542C1 (ru) | Способ получения препарата рекомбинантной нуклеазы CAS, по существу, свободного от бактериальных эндотоксинов, полученный данным способом препарат и содержащий его набор для использования в системе CRISPR/Cas | |
| JP2023134529A (ja) | 新規の最小ｕｔｒ配列 | |
| US11939580B2 (en) | Construct of self-circularization RNA | |
| US11643658B2 (en) | Oligonucleotides, manufacturing method for same, and target RNA site-specific editing method | |
| BR112020005154A2 (pt) | métodos de integração genômica em pichia e outras células hospedeiras | |
| CN116783296A (zh) | 用于募集adar的向导rna的筛选平台 | |
| AR128678A1 (es) | Nickasas cas12a | |
| Chen et al. | Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 RNP | |
| WO2023086938A2 (en) | Type v nucleases | |
| CN118647715A (zh) | 工程化高活性omni-79核酸酶变体 | |
| Ojha et al. | In vitro and in cellula site-directed RNA editing using the λNDD-BoxB system | |
| US20230193243A1 (en) | Compositions comprising a cas12i2 polypeptide and uses thereof | |
| US20230340437A1 (en) | Modified nucleases | |
| CN118581153A (zh) | Dna聚合酶介导的核苷酸序列编辑方法及组合物 | |
| CN117597142A (zh) | Omni 90-99、101、104-110、114、116、118-123、125、126、128、129和131-138 crispr核酸酶 |